On Monday, NetScout Systems, Inc. (NASDAQ:NTCT)’s shares inclined 1.74% to $36.89.
Danaher Corporation (DHR) declared the final exchange ratio for its split-off exchange offer for Danaher common stock in connection with the formerly declared separation of Danaher’s Communications business and merger of Potomac Holding LLC, the Danaher partner holding its Communications business, with a partner of NetScout Systems, Inc. (NTCT) will be 2.4000 common units of Potomac Holding LLC for each share of Danaher common stock validly tendered and not properly withdrawn and accepted by Danaher following the terms of the exchange offer. After Danaher’s acceptance of shares in the exchange offer, a partner of NetScout will merge with and into Potomac Holding LLC, with Potomac Holding LLC surviving the merger and each Potomac Holding LLC common unit will automatically convert into the right to receive one share of NetScout common stock.
The final calculated per-share value of Danaher common shares and the final calculated per-unit value of Potomac Holding LLC common units, in each case determined in the manner described in the Prospectus-Offer to Exchange, dated May 14, 2015 (the “Prospectus”), would have resulted in an exchange ratio of more than the upper limit of 2.4000. Accordingly, the final exchange ratio has been set at 2.4000 Potomac Holding LLC common units for each Danaher common share accepted in the exchange offer. Because the upper limit is in effect, the exchange offer has been automatically extended until 12:00 midnight, New York City time, on July 13, 2015.
NetScout Systems, Inc., together with its auxiliaries, designs, develops, manufactures, markets, licenses, sells, and supports network, application, and service assurance solutions in the United States, Europe, Asia, and internationally. It offers performance analytics and operational intelligence solutions that facilitate the evolution toward new computing paradigms, such as virtualization, mobility, and cloud.
Palatin Technologies, Inc. (NYSEMKT:PTN)’s shares gained 2.72% to $0.945.
Palatin Technologies, Inc. (PTN) FDA Advisory Committee’s recommendation for the approval of flibanserin is an important step forward in women’s health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder, or HSDD, to have an approved treatment option.
HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity, and cannot be accounted for by another medical physical or psychiatric condition, or a substance-like medication. It is estimated that one in 10 women may have the signs of HSDD at some point in their life, and as such HSDD represents a major opportunity to address a tremendous medical need with therapies like flibanserin and bremelanotide.
Palatin Technologies is excited to continue the development of bremelanotide, a first-in-class, as needed, melanocortin-4 receptor agonist being studied for the treatment of HSDD in pre-menopausal women. Bremelanotide has a novel mechanism that activates endogenous pathways in the brain involved in creating a sexual response. It is unique because bremelanotide is an as-needed (not chronic), centrally-mediated medication. Studies have shown that it starts working within 30 to 60 minutes of administration and remains effective for about eight hours, providing women with greater control and flexibility in their treatment.
Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has accomplished Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs comprise Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has accomplished Phase I clinical trial for the treatment of cardiovascular and pulmonary indications, in addition to other melanocortin programs.
At the end of Monday’s trade, Dover Corp (NYSE:DOV)‘s shares surged 1.10% to $66.00.
Dover (DOV) declared that it will release second quarter 2015 earnings at 6:00 a.m. Central time (7:00 a.m. Eastern time) on Tuesday, July 21, 2015. Later that morning, Dover will host a conference call at 9:00 a.m. Central time (10:00 a.m. Eastern time) to talk about these results.
Dover Corporation manufactures and sells a range of equipment and components, specialty systems, and support services in the United States. The company operates in four segments: Energy, Engineered Systems, Fluids, and Refrigeration & Food Equipment. The Energy segment provides solutions and services for the production and processing of oil, natural gas liquids, and gas to drilling and production, bearings and compression, and automation end markets.
Zoetis Inc (NYSE:ZTS), ended its Monday’s trading session with 0.17% gain, and closed at $47.04.
Zoetis Inc.(ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, Aug. 4, 2015. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review second quarter 2015 financial results and respond to questions from financial analysts during the call.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
